Top Railroad Stocks To Invest In Right Now

Not only is today the day of�Berkshire Hathaway's (NYSE: BRK-A  ) (NYSE: BRK-B  ) much-anticipated annual meeting, but it's also the day after Berkshire reported its first-quarter results. It makes sense, then that Buffett might have a few words about the quarter during the annual meeting.

Buffett highlighted a few aspects of the quarterly report. He pointed out that foreign currency movements affected the results -- though he underscored the fact that he doesn't pay much attention to those currency fluctuations as it pertains to the businesses. He also noted the continued performance of the BNSF railroad segment, as well as the fact that oil was found near one of the tracks. "And," Buffett quipped, "what better place to find oil?"

But Buffett had his most glowing comments for GEICO. Buffett said that the positive momentum in both closures -- people inquiring about insurance that actually buy -- and persistence -- policy holders renewing policies -- continued and he views this as a very big positive for GEICO and Berkshire as a whole.

Top Railroad Stocks To Invest In Right Now: CoreSite Realty Corporation(COR)

CoreSite Realty Corporation operates as real investment trust in the United States. The company engages in the ownership, acquisition, construction, and management of data centers. It provides data centers that optimize, secure, and interconnect the mission-critical IT assets of the organizations. The company offers private data centers and suites, cage-to-cabinet colocation, and interconnection services, such as Any2, CoreSite's Internet exchange. Its data centers are located in Los Angeles, the San Francisco Bay and Northern Virginia areas, Chicago, and New York City. The company provides its data centre services to enterprises, cloud providers, financial firms, and Government agencies. As of March 31, 2011, its property portfolio included 11 operating data center facilities, 1 data center under construction, and 1 development site. The company was founded in 2010 and is headquartered in Denver, Colorado.

Advisors' Opinion:

• [By Ong Kang Wei]

  For example, Digital Realty (DLR) is the undoubted leader in the data storage industry, with a market cap of $8.3B. Its other three competitors, DuPont Fabros (DFT), CoreSite Realty (COR) and CyrusOne (CONE), have market caps of $1.5B, $930M and $430M respectively. In addition, with the level of complexity involving Digital's business making it immensely difficult for companies to operate data centre facilities, the company is in a good position for future growth. The company also has a wide network of 595 tenants (significantly more than other competitors), including CenturyLink (CTL), AT&T and Morgan Stanley (MS). This further secures its long term business prospects and also its dominance over its competitors.

• [By Monica Wolfe]

  CoreSite Realty Corp (COR)

  During the second quarter, Columbia Wanger increased their holdings in CoreSite Realty by 256.43%. The fund purchased a total of 1,176,650 shares of the company�� stock. They purchased these shares at an average price of $34.19 and since then the price per share has increased an additional 4.1%.

• [By Dividends4Life]

  CoreSite Realty Corporation (COR) engages in the ownership, acquisition, construction, and management of data centers. December 5th the company increased its quarterly dividend 30% to $0.35 per share. The dividend is payable January 15, 2014, to shareholders of record on December 31, 2013. The yield based on the new payout is 4.7%.

Top Railroad Stocks To Invest In Right Now: Universal Corporation(UVV)

Universal Corporation, together with its subsidiaries, operates as a leaf tobacco merchant and processor worldwide. It engages in selecting, procuring, buying, processing, packing, storing, supplying, shipping, and financing leaf tobacco for sale to, or for the account of, manufacturers of consumer tobacco products. The company processes and/or sells flue-cured and burley tobaccos, dark air-cured tobaccos, and oriental tobaccos; and provides value-added services, including blending, chemical and physical testing of tobacco, just-in-time inventory management, and manufacturing reconstituted sheet tobacco. Its flue-cured, burley, and oriental tobaccos are used principally in the manufacture of cigarettes; and dark air-cured tobaccos are used in the manufacture of cigars, pipe tobacco, and smokeless tobacco products. The company was founded in 1888 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By Rupert Hargreaves]

  Universal Corp (NYSE: UVV  ) has paid out and raised its dividend for 41 consecutive years. This puts the company in an elite club of dividend aristocrats.�Aside from Altria (NYSE: MO  ) , which has been paying and increasing its payout for 43 years, Universal actually has the longest dividend history of any company within the tobacco sector.

• [By Marc Bastow]

  Leaf tobacco supplier Universal Corporation (UVV) raised its quarterly dividend 2% to 51 cents per share, payable on Feb. 10 to shareholders of record as of Jan. 13.
  UVV Dividend Yield: 4.06%
  

Top Blue Chip Stocks To Watch Right Now: Cabot Microelectronics Corporation(CCMP)

Cabot Microelectronics Corporation engages in the development, manufacture, and sale of chemical mechanical planarization (CMP) consumables to the semiconductor industry primarily in the United States, Asia, and Europe. CMP is a polishing process used by integrated circuit (IC) device manufacturers to planarize or flatten the multiple layers of material that are deposited upon silicon wafers in the production of advanced ICs. The company offers CMP slurries, which are liquid solutions composed of high-purity deionized water, proprietary chemical additives, and engineered abrasives that chemically and mechanically interact with the surface material of the IC device at an atomic level; and CMP polishing pads that are engineered polymeric materials designed to distribute and transport the slurry to the surface of the wafer and distribute it evenly across the wafer. Its CMP slurries are used for various polishing applications, including materials that conduct electrical signal s, such as tungsten, copper, tantalum, and aluminum; the dielectric insulating materials that separate conductive layers within logic and memory IC devices; and the disk substrates and magnetic heads used in hard disk drives. The company also designs and produces precision polishing and metrology systems to attain shape and surface finish on various optical components, such as mirrors, lenses, and prisms. It serves producers of logic IC devices and memory IC devices, as well as IC foundries. The company was founded in 1999 and is headquartered in Aurora, Illinois.

Advisors' Opinion:

• [By Nikolaj Gammeltoft]

  Not all of Granville�� best calls were in the distant past. On March 11, 2000, the day after the Nasdaq Composite Index (CCMP) jumped to a record 5048.62, Granville wrote that investors in technology stocks ��ill soon be burned.��The index, heavy on computer-related companies, tumbled about 78 percent before bottoming on Oct. 9, 2002.

• [By Whitney Kisling]

  That alert proved too optimistic and the exchange pushed back the open another 15 minutes. By 3:25 p.m., Nasdaq stocks started ticking again. With the close about 35 minutes away, both the Nasdaq Composite Index (CCMP) and the Nasdaq 100 Index began to rise.

Top Railroad Stocks To Invest In Right Now: Intercontinentalexchange Group Inc (ICE)

IntercontinentalExchange Group, Inc., incorporated on March 6, 2013, is a network of regulated exchanges and clearing houses for financial and commodity markets. The Company delivers transparent and accessible data, technology and risk management services to markets around the world through its portfolio of exchanges, including the New York Stock Exchange, ICE Futures, Liffe and Euronext. In February 2014, Intercontinentalexchange Group Inc completed the acquisition of Singapore Mercantile Exchange.

In November 2013, the Company announced the acquisition of NYSE Euronext. In November 2013, Financial Technologies (India) Ltd announced that Financial Technologies Singapore Pte. Ltd., a wholly owned subsidiary of Financial Technologies (India) Ltd., sold its ownership in SMX (together with its wholly owned subsidiary SMX CC) to ICE Singapore Holdings Pte. Ltd., an entity owned by the Intercontinentalexchange Group Inc.

Advisors' Opinion:

• [By Nikolaj Gammeltoft]

  U.S. securities regulators approved IntercontinentalExchange Inc. (ICE)�� acquisition of NYSE Euronext (NYX), bringing the company one step closer to taking over some of the biggest stock and derivatives exchanges in America and Europe.

• [By Eric Volkman]

  IntercontinentalExchange's (NYSE: ICE  ) impending acquisition of NYSE Euronext (NYSE: NYX  ) doesn't pose enough of a threat to competition to warrant concern, at least according to the European Commission. As a result, the European Union's executive branch has approved the proposed transaction, saying that it does not "raise competition concerns as NYX and ICE are not direct competitors in the markets concerned and would continue to face competition from a number of other competitors."

Top Railroad Stocks To Invest In Right Now: Quest Diagnostics Inc (DGX)

Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.

Clinical Testing

The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.

The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing through its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.

The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical director services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.

The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.

In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.

Healthcare Information Technology

The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic document management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics��Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient�� account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.

Clinical Trials Testing

The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People�� Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.

Life Insurer Services

The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant�� home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examinations. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.

Employer Services

The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation�� workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.

Diagnostic Products

Diagnostic Products include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are sold under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.

HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.

The Company competes with Laboratory Corporation of America Holdings, Inc.

Advisors' Opinion:

• [By Rich Duprey]

  Diagnostic information services provider Quest Diagnostics (NYSE: DGX  ) announced yesterday that it had completed the acquisition of the clinical outreach services of Dignity Health, a California-based hospital.